Changes in motor subtype and risk for incident dementia in Parkinson's disease

Movement Disorders

Volumn 21, Issue 8, 2006, Pages 1123-1130

  Alves, Guido ^a,b   Larsen, Jan Petter ^a,b   Emre, Murat ^c   Wentzel Larsen, Tore ^d   Aarsland, Dag ^a,b  

^a Norwegian Centre for Movement Disorders   (Norway)

^b STAVANGER UNIVERSITY HOSPITAL   (Norway)

^c ISTANBUL UNIVERSITY   (Turkey)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cognitive impairment; Dementia; Gait disorder; Parkinson's disease; Postural instability; Postural instability gait difficulty

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

ADULT; AGED; ARTICLE; BODY POSTURE; COGNITION; COGNITIVE DEFECT; COMMUNITY CARE; CONTROLLED STUDY; DEMENTIA; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE COURSE; FEMALE; FOLLOW UP; GAIT DISORDER; HUMAN; INTERVIEW; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MOTOR DYSFUNCTION; NEUROPSYCHOLOGICAL TEST; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PROSPECTIVE STUDY; RATING SCALE; RISK ASSESSMENT;

AGED; COGNITION DISORDERS; DEMENTIA; DEMOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; MOTOR ACTIVITY; PARKINSON DISEASE; REFERENCE VALUES; RISK ASSESSMENT; TIME FACTORS; TREMOR;

EID: 33748357972     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.20897     Document Type: Article

References (51)

1. Lang AE, Obeso JA. Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol 2004;3:309-316.
2. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
3. Braak H, Rub U, Jansen Steur EN, Del Tredici K, de Vos RA. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 2005;64:1404-1410.
4. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol 2003;2:229-237.
5. Pahapill PA, Lozano AM. The pedunculopontine nucleus and Parkinson's disease. Brain 2000;123(Pt. 9):1767-1783.
6. Lee MS, Rinne JO, Marsden CD. The pedunculopontine nucleus: its role in the genesis of movement disorders. Yonsei Med J 2000;41:167-184.
7. Aarsland D, Larsen JP, Karlsen K, Lim NG, Tandberg E. Mental symptoms in Parkinson's disease are important contributors to caregiver distress. Int J Geriatr Psychiatry 1999;14:866-874.
8. Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J Am Geriatr Soc 2000;48:938-942.
9. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry 2000;69:308-312.
10. Emre M. What causes mental dysfunction in Parkinson's disease? Mov Disord 2003;18(Suppl. 6):S63-S71.
11. Bum DJ, Rowan EN, Minett T, et al. Extrapyramidal features in Parkinson's disease with and without dementia and dementia with Lewy bodies: a cross-sectional comparative study. Mov Disord 2003;18:884-889.
12. Levy G, Tang MX, Cote LJ, et al. Motor impairment in PD: relationship to incident dementia and age. Neurology 2000;55: 539-544.
13. Tandberg E, Larsen JP, Nessler EG, Riise T, Aarli JA. The epidemiology of Parkinson's disease in the county of Rogaland, Norway. Mov Disord 1995;10:541-549.
14. Larsen JP, Dupont E, Tandberg E. Clinical diagnosis of Parkinson's disease: proposal of diagnostic subgroups classified at different levels of confidence. Acta Neurol Scand 1994;89:242-251.
15. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
16. Fahn S, Elton R, members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn SMC, Calne DB, Lieberman A, editors. Recent development in Parkinson disease. Florham Park, NJ: Macmillan Health Care information; 1987. p 153-163.
17. Jankovic J, McDermott M, Carter J, et al. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort - the Parkinson Study Group. Neurology 1990;40:1529-1534.
18. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, revised 3rd edition. Washington, DC: American Psychiatric Association; 1987.
19. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
20. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389.
21. Gottfries CG, Bråne G, Gullberg B, Steen G. A new rating scale for dementia syndromes. Arch Gerontol Geriatr 1982;1:311-330.
22. Brown GG, Rabill AA, Gorell JM, et al. Validity of the Dementia Rating Scale in assessing cognitive function in Parkinson's disease. J Geriatr Psychiatry Neurol 1999;12:180-188.
23. Benton AL. The revised visual retention test, 4th ed. New York: Psychological Corporation; 1974.
24. Golden JC. Stroop color and word test. Chicago: Stoelting; 1978.
25. Benton AL, Varney NR, Hamsher KD. Visuospatial judgment: a clinical test. Arch Neurol 1978;35:364-367.
26. Crum RM, Anthony JC, Bassett SS, Folstein MF. Population-based norms for the Mini-Mental State Examination by age and educational level. JAMA 1993;269:2386-2391.
27. Lucas JA, Ivnik RJ, Smith GE, et al. Normative data for the Mattis Dementia Rating Scale. J Clin Exp Neuropsychol 1998;20:536-547.
28. Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sorensen P. Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology 2001;56:730-736.
29. Hosmer DW, Lemeshow S. Applied logistic regression. New York: John Wiley and Sons; 2000.
30. Louis ED, Tang MX, Cote L, Alfaro B, Mejia H, Marder K. Progression of parkinsonian signs in Parkinson disease. Arch Neurol 1999;56:334-337.
31. Paulson HLSM. Clinical manifestations of Parkinson's disease. In: Watts RLKW, editor. Movement disorders: neurologic principles and practice. New York: McGraw-Hill; 1997. p 183-199.
32. Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol 1991;50:743-755.
33. Jellinger KA. Postmortem studies in Parkinson's disease: is it possible to detect brain areas for specific symptoms? J Neural Transm 1999;56(Suppl.):1-29.
34. Schiess MC, Zheng H, Soukup VM, Bonnen JG, Nauta HJ. Parkinson's disease subtypes: clinical classification and ventricular cerebrospinal fluid analysis. Parkinsonism Relat Disord 2000;6: 69-76.
35. Aarsland D, Andersen K, Larsen JP, et al. The rate of cognitive decline in Parkinson disease. Arch Neurol 2004;61:1906-1911.
36. Bergman H, Deuschl G. Pathophysiology of Parkinson's disease: from clinical neurology to basic neuroscience and back. Mov Disord 2002;17(Suppl. 3):S28-S40.
37. Chapman CA, Yeomans JS, Blaha CD, Blackburn JR. Increased striatal dopamine efflux follows scopolamine administered systemically or to the tegmental pedunculopontine nucleus. Neuroscience 1997;76:177-186.
38. German DC, White CL III, Sparkman DR. Alzheimer's disease: neurofibrillary tangles in nuclei that project to the cerebral cortex. Neuroscience 1987;21:305-312.
39. Juncos JL, Hirsch EC, Malessa S, Duyckaerts C, Hersh LB, Agid Y. Mesencephalic cholinergic nuclei in progressive supranuclear palsy. Neurology 1991;41:25-30.
40. Lopez OL, Wisnieski SR, Becker JT, Boller F, DeKosky ST. Extrapyramidal signs in patients with probable Alzheimer disease. Arch Neurol 1997;54:969-975.
41. Mathur A, Shandarin A, LaViolette SR, Parker J, Yeomans JS. Locomotion and stereotypy induced by scopolamine: contributions of muscarinic receptors near the pedunculopontine tegmental nucleus. Brain Res 1997;775:144-155.
42. Nandi D, Aziz TZ, Giladi N, Winter J, Stein JF. Reversal of akinesia in experimental parkinsonism by GABA antagonist microinjections in the pedunculopontine nucleus. Brain 2002;125(Pt. 11):2418-2430.
43. Zweig RM, Whitehouse PJ, Casanova MF, Walker LC, Jankel WR, Price DL. Loss of pedunculopontine neurons in progressive supranuclear palsy. Ann Neurol 1987;22:18-25.
44. Zweig RM, Jankel WR, Hedreen JC, Mayeux R, Price DL. The pedunculopontine nucleus in Parkinson's disease. Ann Neurol 1989;26:41-46.
45. Perry EK, Curtis M, Dick DJ, et al. Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry 1985;48:413-421.
46. Perry EK, McKeith I, Thompson P, et al. Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson's disease, and Alzheimer's disease. Ann NY Acad Sci 1991;640:197-202.
47. Inglis WL, Olmstead MC, Robbins TW. Selective deficits in attentional performance on the 5-choice serial reaction time task following pedunculopontine tegmental nucleus lesions. Behav Brain Res 2001;123:117-131.
48. Ivlieva NY, Timofeeva NO. Activity of neurons in the pedunculopontine nucleus during a food-related operant conditioned reflex. Neurosci Behav Physiol 2003;33:919-928.
49. Levy G, Tang MX, Louis ED, et al. The association of incident dementia with mortality in PD. Neurology 2002;59:1708-1713.
50. Lozano AM, Lang AE, Galvez-Jimenez N, et al. Effect of Gpi pallidotomy on motor function in Parkinson's disease. Lancet 1995;346:1383-1387.
51. Jankovic J, Kapadia AS. Functional decline in Parkinson disease. Arch Neurol 2001;58:1611-1615.